331 related articles for article (PubMed ID: 17498784)
21. Preoperative serum tetranectin, CA125 and menopausal status used as single markers in screening and in a risk assessment index (RAI) in discriminating between benign and malignant ovarian tumors.
Begum FD; Høgdall E; Kjaer SK; Blaakaer J; Christensen IJ; Christensen L; Høgdall C
Gynecol Oncol; 2009 May; 113(2):221-7. PubMed ID: 19261323
[TBL] [Abstract][Full Text] [Related]
22. Value of serum CA125 levels in patients with high-risk, early stage epithelial ovarian cancer.
Kang WD; Choi HS; Kim SM
Gynecol Oncol; 2010 Jan; 116(1):57-60. PubMed ID: 19818996
[TBL] [Abstract][Full Text] [Related]
23. The immunomodulatory protein B7-H4 is overexpressed in breast and ovarian cancers and promotes epithelial cell transformation.
Salceda S; Tang T; Kmet M; Munteanu A; Ghosh M; Macina R; Liu W; Pilkington G; Papkoff J
Exp Cell Res; 2005 May; 306(1):128-41. PubMed ID: 15878339
[TBL] [Abstract][Full Text] [Related]
24. Statistical interpretation of CA125 and Bcl-2 in serum of patients with late stage ovarian cancer.
Camlica H; Duranyildiz D; Tas F; Yasasever V
Am J Clin Oncol; 2008 Dec; 31(6):585-8. PubMed ID: 19060592
[TBL] [Abstract][Full Text] [Related]
25. Relationship of serum levels of tumor markers with tissue expression of gene products in ovarian carcinoma.
Sorak M; Arsenijević S; Lukić G; Arsenijević N; Ristić P; Pavlović S; Popović S; Baskić D
J BUON; 2007; 12(1):99-104. PubMed ID: 17436409
[TBL] [Abstract][Full Text] [Related]
26. Comparison between soluble tumor necrosis factor receptors and CA125 in peritoneal fluids as a marker for epithelial ovarian cancer.
Onsrud M; Shabana A; Austgulen R; Nustad K
Gynecol Oncol; 1995 May; 57(2):183-7. PubMed ID: 7729731
[TBL] [Abstract][Full Text] [Related]
27. Relationship between B7-H4, regulatory T cells, and patient outcome in human ovarian carcinoma.
Kryczek I; Wei S; Zhu G; Myers L; Mottram P; Cheng P; Chen L; Coukos G; Zou W
Cancer Res; 2007 Sep; 67(18):8900-5. PubMed ID: 17875732
[TBL] [Abstract][Full Text] [Related]
28. Characterization of serum biomarkers for detection of early stage ovarian cancer.
Kozak KR; Su F; Whitelegge JP; Faull K; Reddy S; Farias-Eisner R
Proteomics; 2005 Nov; 5(17):4589-96. PubMed ID: 16237736
[TBL] [Abstract][Full Text] [Related]
29. Human kallikrein 8 protein is a favorable prognostic marker in ovarian cancer.
Borgoño CA; Kishi T; Scorilas A; Harbeck N; Dorn J; Schmalfeldt B; Schmitt M; Diamandis EP
Clin Cancer Res; 2006 Mar; 12(5):1487-93. PubMed ID: 16533772
[TBL] [Abstract][Full Text] [Related]
30. Elevated serum RANTES levels in patients with ovarian cancer correlate with the extent of the disorder.
Tsukishiro S; Suzumori N; Nishikawa H; Arakawa A; Suzumori K
Gynecol Oncol; 2006 Sep; 102(3):542-5. PubMed ID: 16510173
[TBL] [Abstract][Full Text] [Related]
31. Preoperative tumor marker CA125 levels in relation to epithelial ovarian cancer stage.
Fures R; Buković D; Hodek B; Klarić B; Herman R; Grubisić G
Coll Antropol; 1999 Jun; 23(1):189-94. PubMed ID: 10402722
[TBL] [Abstract][Full Text] [Related]
32. The use of multiple novel tumor biomarkers for the detection of ovarian carcinoma in patients with a pelvic mass.
Moore RG; Brown AK; Miller MC; Skates S; Allard WJ; Verch T; Steinhoff M; Messerlian G; DiSilvestro P; Granai CO; Bast RC
Gynecol Oncol; 2008 Feb; 108(2):402-8. PubMed ID: 18061248
[TBL] [Abstract][Full Text] [Related]
33. Evaluation of the novel serum markers B7-H4, Spondin 2, and DcR3 for diagnosis and early detection of ovarian cancer.
Simon I; Liu Y; Krall KL; Urban N; Wolfert RL; Kim NW; McIntosh MW
Gynecol Oncol; 2007 Jul; 106(1):112-8. PubMed ID: 17490732
[TBL] [Abstract][Full Text] [Related]
34. [Clinical value of serum CA19-9, CA125 and CP2 in mucinous ovarian tumor: a retrospective study of 273 patients].
Dong L; Cui H; Li XP; Sun LF; Chang XH; Liang XD; Zhu HL
Zhonghua Fu Chan Ke Za Zhi; 2008 Jan; 43(1):5-8. PubMed ID: 18366923
[TBL] [Abstract][Full Text] [Related]
35. IMMULITE OM-MA assay: a useful diagnostic tool in patients with benign and malignant ovarian tumors.
Gebauer G; Rieger M; Jäger W; Lang N
Anticancer Res; 1999; 19(4A):2535-6. PubMed ID: 10470190
[TBL] [Abstract][Full Text] [Related]
36. Human kallikrein 11: an indicator of favorable prognosis in ovarian cancer patients.
Diamandis EP; Borgoño CA; Scorilas A; Harbeck N; Dorn J; Schmitt M
Clin Biochem; 2004 Sep; 37(9):823-9. PubMed ID: 15329323
[TBL] [Abstract][Full Text] [Related]
37. Serum tetranectin and CA125 in endometrial adenocarcinoma.
Lundstrøm MS; Høgdall CK; Nielsen AL; Nyholm HC
Anticancer Res; 2000; 20(5C):3903-6. PubMed ID: 11268474
[TBL] [Abstract][Full Text] [Related]
38. [Relationship between tumor markers and clinical symptoms in ovarian cancer].
Yakushiji M; Nishimura H
Rinsho Byori; 1992 Apr; 40(4):354-8. PubMed ID: 1593760
[TBL] [Abstract][Full Text] [Related]
39. [The clinical value of tissue polypeptide antigen in ovarian carcinoma].
Wu L; Sun J; Wang X
Zhonghua Fu Chan Ke Za Zhi; 1998 Feb; 33(2):92-4. PubMed ID: 10682428
[TBL] [Abstract][Full Text] [Related]
40. Relapse and survival in early-stage ovarian cancer.
Lenhard SM; Bufe A; Kümper C; Stieber P; Mayr D; Hertlein L; Kirschenhofer A; Friese K; Burges A
Arch Gynecol Obstet; 2009 Jul; 280(1):71-7. PubMed ID: 19093129
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
